Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Non-interventional study DECIDE II: First patients included

We are very pleased to announce that we have started our new non-interventional observational study entitled “Decision for or against anti-PD1 Treatment In Adjuvant Setting of Patients across Europe with Resected Stage IIB/IIC Melanoma (DECIDE II)" in collaboration with Merck, Sharpe and Dohme LCC and have already enrolled the first patients. This is an important step for our project, and we look forward to further recruitment.

Many thanks to everyone involved for their support. We will keep you informed about the progress of the study.

Are you interested in participating in this multinational study? Please contact us at office@eumelareg.org.